To Solve the Problem of Amplification Products Contamination in the Process of SARS-CoV-2 Nucleic Acid Testing: Substitution Strategies between Kits

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. The timing and efficiency of new coronavirus diagnosis continues to play an important role in the treatment and detection of the patients with critical conditions. Reverse transcription-quantitative PCR (RT-qPCR)-based tests are widely used to diagnose coronavirus disease 2019 (COVID-19). To achieve high accuracy and rapid diagnostic performance, laboratories must address the problems of false positives and cross-contamination encountered during testing in nucleic acid testing laboratories. In this study, sequencing technology was used to compare the targeting sequences between 19 novel coronavirus nucleic acid detection kits that have been approved in China by the National Medical Products Administration (NMPA). The aim is to solve the problem of false positives and contamination in the laboratory, and to provide a replacement solution between kits in case of positive nucleic acid products contamination in the laboratory to provide value to the treatment of critically ill or asymptomatic infected patients.